First-Pass Metabolism and Ketamine Tablet

If you've wondered why your ketamine tablet dose is so much larger than what's used in IV infusions, or why taking ketamine tablet feels different from what patients describe after IV treatment, the answer lies largely in first-pass metabolism. This hepatic process fundamentally shapes the pharmacology of ketamine tablet and is one of the most important concepts for patients and clinicians to understand.

What Is First-Pass Metabolism?

When you swallow a drug, it must travel through the gastrointestinal tract, be absorbed across the intestinal wall, and then travel through the portal vein to the liver — all before reaching systemic circulation. This initial passage through the liver is called the "first pass," and the metabolic transformation that occurs there is first-pass (or presystemic) metabolism.

The liver is the body's primary metabolic organ, containing enormous concentrations of drug-metabolizing enzymes. For many drugs, the liver extracts and transforms a significant fraction of the absorbed dose on this first pass, reducing the amount of unchanged drug that ultimately enters circulation.

For ketamine, this hepatic extraction is extensive: approximately 75 to 90 percent of absorbed ketamine is metabolized during the first pass, explaining the drug's low oral bioavailability of 10 to 25 percent.

The Enzymes Responsible

Ketamine's first-pass metabolism is carried out primarily by cytochrome P450 enzymes:

CYP3A4

CYP3A4 is the most abundant hepatic cytochrome P450 enzyme and the primary metabolizer of ketamine. It catalyzes the N-demethylation of ketamine to form norketamine. CYP3A4 is also present in significant quantities in the intestinal wall, contributing to pre-hepatic metabolism even before the drug reaches the liver. This is one reason why food intake and certain medications can significantly alter ketamine absorption.

CYP2B6

CYP2B6 plays a secondary but meaningful role in ketamine metabolism, particularly at lower drug concentrations. Genetic polymorphisms in CYP2B6 contribute to inter-individual variability in ketamine metabolism.

CYP2C9

CYP2C9 contributes to a lesser extent to ketamine N-demethylation.

The Metabolic Pathway: Ketamine to Norketamine

The primary first-pass reaction converts ketamine to norketamine via N-demethylation — the removal of a methyl group from the nitrogen atom in the ketamine molecule.

After this initial conversion:

• Norketamine undergoes further metabolism to hydroxynorketamine (HNK) compounds
• HNK metabolites are then conjugated and excreted in urine
• The entire metabolic cascade produces numerous minor metabolites

The half-life of ketamine itself is approximately 2 to 3 hours. Norketamine has a longer half-life of 4 to 6 hours, meaning it persists in the body significantly longer than the parent compound after oral dosing.

Why Oral Doses Must Be Higher

Because 75–90% of absorbed ketamine is removed during the first pass, oral doses must be substantially higher than IV doses to achieve comparable plasma concentrations of the parent drug. Here's a simplified example:

• IV dose: 0.5 mg/kg → essentially 100% reaches circulation → therapeutic plasma levels achieved
• Oral dose: 3–6 mg/kg → ~15–20% reaches circulation → similar plasma levels achieved

In absolute terms for a 70 kg adult:

• IV: ~35 mg to achieve effect
• Oral: 210–420 mg may be needed for comparable exposure

However, this comparison is imprecise because oral therapy typically does not aim to replicate IV plasma levels — it pursues different therapeutic goals (maintenance, low-dose chronic dosing) that don't require the same peak concentrations.

Norketamine: The Active Metabolite

A critical insight in ketamine tablet pharmacology is that norketamine is not merely a waste product — it is pharmacologically active. This matters enormously because oral dosing generates far more norketamine relative to ketamine than IV administration does.

Norketamine's Pharmacological Profile

• NMDA receptor antagonist at approximately one-third to one-fifth the potency of ketamine
• Less affinity for opioid receptors compared to ketamine
• Less dissociative effect at equivalent concentrations
• Longer duration of action due to longer half-life
• May have independent antidepressant properties

Hydroxynorketamine (HNK)

Research, particularly work by Costi, Bhatt, and colleagues, has revealed that (2R,6R)-hydroxynorketamine — a downstream metabolite of norketamine — may independently contribute to antidepressant effects through AMPA receptor potentiation rather than NMDA antagonism. This finding suggests that the full metabolic cascade from ketamine tablet may actually be therapeutically beneficial, not just an obstacle to overcome.

Factors That Alter First-Pass Metabolism

First-pass metabolism is not fixed — it varies considerably between individuals and within the same individual based on multiple factors:

Genetic Polymorphisms

CYP3A4 and CYP2B6 genes are highly polymorphic. Individuals may be:

• Poor metabolizers: Higher ketamine, lower norketamine; potentially more intense effects from a given dose
• Extensive metabolizers (most common): Average metabolism
• Ultra-rapid metabolizers: Lower ketamine, higher norketamine; may need higher doses for effect

Pharmacogenomic testing can identify relevant variants, though it is not yet standard of care for ketamine prescribing.

Drug-Drug Interactions

Many commonly prescribed medications affect CYP3A4 activity:

Inhibitors (increase ketamine levels by slowing first-pass metabolism):

• Fluconazole, itraconazole (antifungals)
• Clarithromycin, erythromycin (antibiotics)
• Ritonavir and other HIV protease inhibitors
• Grapefruit juice (natural CYP3A4 inhibitor)

Inducers (decrease ketamine levels by accelerating metabolism):

• Rifampin (antibiotic)
• Carbamazepine, phenytoin (anticonvulsants)
• St. John's Wort (herbal supplement)
• Chronic alcohol use

Patients taking any of these should discuss dose adjustments with their prescriber.

Liver Disease

Hepatic impairment from any cause (cirrhosis, hepatitis, fatty liver disease) reduces the liver's metabolic capacity. Patients with significant liver disease may have substantially higher ketamine bioavailability, increasing both therapeutic effect and risk of adverse effects. Dose reduction is typically required.

Age

Hepatic blood flow and enzyme activity decline with age. Elderly patients may have higher ketamine bioavailability from first-pass reduction, warranting conservative dosing.

Alcohol Consumption

Acute alcohol use inhibits CYP enzymes and may temporarily increase ketamine exposure. Chronic heavy drinking induces CYP enzymes and may reduce bioavailability. Patients are typically advised to avoid alcohol around their ketamine doses.

Clinical Implications

Understanding first-pass metabolism helps patients and clinicians:

1. Set appropriate dose expectations: Higher oral doses are not a sign of tolerance or failure — they reflect the pharmacological reality of the oral route
2. Anticipate different effects than IV: The norketamine-rich profile of oral dosing produces a gentler, longer-lasting effect than the ketamine-dominated IV experience
3. Manage drug interactions proactively: Reporting all medications and supplements to your prescriber is essential for safe dosing
4. Recognize that the "weaker" oral route has unique benefits: The norketamine and HNK metabolites generated during first-pass metabolism may contribute independently to therapeutic outcomes

First-pass metabolism is not merely a pharmacokinetic inconvenience — it is a defining feature of ketamine tablet that shapes its clinical character and therapeutic profile.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
• WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches